DK0701449T3 - Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac - Google Patents

Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac

Info

Publication number
DK0701449T3
DK0701449T3 DK94918361T DK94918361T DK0701449T3 DK 0701449 T3 DK0701449 T3 DK 0701449T3 DK 94918361 T DK94918361 T DK 94918361T DK 94918361 T DK94918361 T DK 94918361T DK 0701449 T3 DK0701449 T3 DK 0701449T3
Authority
DK
Denmark
Prior art keywords
dosage form
pct
preparation
solid dosage
oral solid
Prior art date
Application number
DK94918361T
Other languages
Danish (da)
English (en)
Inventor
Peter Heinrich Stahl
Claudio Gamboni
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0701449T3 publication Critical patent/DK0701449T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK94918361T 1993-06-08 1994-05-24 Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac DK0701449T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH171193 1993-06-08
PCT/EP1994/001662 WO1994028936A1 (en) 1993-06-08 1994-05-24 Process for the preparation of an oral solid dosage form containing diclofenac

Publications (1)

Publication Number Publication Date
DK0701449T3 true DK0701449T3 (da) 2003-11-10

Family

ID=4216820

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94918361T DK0701449T3 (da) 1993-06-08 1994-05-24 Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac

Country Status (14)

Country Link
US (1) US5702724A (ja)
EP (1) EP0701449B1 (ja)
JP (2) JPH08511009A (ja)
AT (1) ATE246515T1 (ja)
AU (1) AU6971294A (ja)
CA (1) CA2163111C (ja)
DE (1) DE69433012T2 (ja)
DK (1) DK0701449T3 (ja)
ES (1) ES2204918T3 (ja)
FI (1) FI116039B (ja)
NO (1) NO315844B1 (ja)
NZ (1) NZ267417A (ja)
PT (1) PT701449E (ja)
WO (1) WO1994028936A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0800384T3 (da) * 1994-12-14 2001-04-17 Enbalt Trading Ltd Pharmaceutiske tabletformuleringer til direkte kompression
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
JP2005298338A (ja) * 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
US20050123604A1 (en) * 2002-03-07 2005-06-09 Karnachi Anees A. Pharmaceutical compositions
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
DE102004060914A1 (de) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
EP1707217A1 (en) * 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
KR20160033796A (ko) * 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
EP2003970A4 (en) * 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF NON-STEROID ANTI-INFLAMMATORY DRUGS WITH LOW DOSE AND BETA-CYCLODEXTRIN
US20110144207A1 (en) * 2008-08-14 2011-06-16 Shasun Chemicals And Drugs Limited Aryl alkyl carboxylic acid salts, process for preparation and dosage forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959632A (ja) * 1982-09-28 1984-04-05 Teikoku Chem Ind Corp Ltd 徐放性組成物
JPS5984821A (ja) * 1982-11-04 1984-05-16 Teikoku Chem Ind Corp Ltd 徐溶化組成物
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
IT1243342B (it) * 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
DE69013689T2 (de) * 1990-11-29 1995-03-02 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte Verpressung.
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Also Published As

Publication number Publication date
US5702724A (en) 1997-12-30
FI955837A0 (fi) 1995-12-04
JPH08511009A (ja) 1996-11-19
DE69433012D1 (de) 2003-09-11
ES2204918T3 (es) 2004-05-01
EP0701449A1 (en) 1996-03-20
FI116039B (fi) 2005-09-15
NO954952L (no) 1995-12-06
NO315844B1 (no) 2003-11-03
NZ267417A (en) 1997-02-24
FI955837A (fi) 1995-12-04
ATE246515T1 (de) 2003-08-15
WO1994028936A1 (en) 1994-12-22
JP2005247874A (ja) 2005-09-15
CA2163111C (en) 2010-10-26
PT701449E (pt) 2003-12-31
AU6971294A (en) 1995-01-03
NO954952D0 (no) 1995-12-06
DE69433012T2 (de) 2004-06-09
CA2163111A1 (en) 1994-12-22
EP0701449B1 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
BG102259A (en) Compostions with controlled paroxetine release
DE69705300T2 (de) Cyclopropylalkansäurederivate
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DK0701449T3 (da) Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
EP1026157A3 (en) Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
BR9509975A (pt) Formulação farmacêutica
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
DK0557389T3 (da) Fremgangsmåde til fremstilling af tabletter indeholdende cephalosporansyrederivater ved direkte komprimering
AU4304596A (en) A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
FI950209A (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
DK0850225T3 (da) Mellemprodukt til fremstilling af en farmaceutisk aktiv forbindelse
SE9304065D0 (sv) New compound
HU9401159D0 (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them